Monitoring Agency Report

August 14, 2026 To, To, Listing Department, The National Stock Exchange of India BSE Limited Ltd. Phiroze Jeejeebhoy Towers, The Listing Department Dalal Street, Exchange Plaza, Mumbai – 400 001 Bandra – Kurla Complex, Ref: BSE Scrip Code: 544497 Mumbai – 400051, NSE Scrip Code: AHCL Sub: Submission of Monitoring Agency Report for the quarter ended June 30, 2026. Dear Sir/Madam, Pursuant to Regulation 30 and 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 41(2) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”), please find enclosed herewith the Monitoring Agency Report issued by CRISIL RATINGS LIMITED for the quarter ended June 30, 2026. You are requested to take the above information on your record. Thanking You. Yours Faithfully, For ANLON HEALTHCARE LIMITED PUNITKUMAR RASADIA MANAGING DIRECTOR DIN: 06696258 ANLON HEALTHCARE LIMITED CIN No.: L24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in Monitoring Agency Report Anlon Healthcare Limited for the quarter ended June 30, 2026 CRL/MAR/ANLHLP/2026-27/1956 August 14, 2026 Anlon Healthcare Limited 101/102, Silvercoin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot – 360 005, Gujarat, India Dear Sir, Sub: Final Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the Initial Public Offer (“IPO”) of Anlon Healthcare Limited (“the Company”) Pursuant to Regulation 41(2) of SEBI (lssue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and Monitoring Agency Agreement dated August 12, 2025, enclosed herewith the Final Monitoring Agency Report, issued by Crisil Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of IPO for the quarter ended June 30, 2026. Request you to kindly take the same on records. Thanking you, For and on behalf of Crisil Ratings Limited Shounak Chakravarty Director, Ratings (LCG) Final Report of the Monitoring Agency (MA) Name of the issuer: Anlon Healthcare Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: Crisil Ratings Limited (a) Deviation from the objects: No, Refer Note 1 Note 1: During the quarter ending March 31, 2026, deviation was observed in the utilization of funds against the objects stated in the Prospectus however, utilization was in line with change of objects as per the Shareholder’s approval dated January 07, 2026. Specifically, the Company has expanded the scope of the object viz. “Funding capital expenditure requirements for expansion of Manufacturing Facility (“Proposed Expansion”)” and added “proposed expansion through inorganic growth and further upgradations” (b) Range of Deviation: Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Shounak Chakravarty Designation of Authorized person/Signing Authority: Director, Ratings (LCG) 1) Issuer Details: Name of the issuer: Anlon Healthcare Limited Names of the promoter: a. Punit Kumar R Rasadia b. Meet Atul Kumar Vachhani Industry/sector to which it belongs: Pharmaceuticals 2) Issue Details Issue Period: Tuesday, August 26, 2025, to Friday, August 29, 2025 Type of issue (public/rights): Initial Public Offer (IPO) Type of specified securities: Equity Shares IPO Grading, if any: NA Issue size: Fresh Issue - Rs 12,103.00 lakh* *Note: Particulars Amount (Rs lakh) Gross proceeds of the Fresh Issue 12,103.00# Less: Revised Issue Expenses 1428.66 (Refer Note 2) Revised Net Proceeds 10,674.34 (Refer Note 2) #Crisil Ratings shall be monitoring the gross proceeds. 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information/ Comments Comments certifications considered of the Particulars Reply of the Board by Monitoring Agency Monitoring of Directors for preparation of report Agency Statutory Auditor certificate^, Management undertaking, Prospectus Whether all utilization is as per the disclosures dated August 30, 2025 No No in the Offer Document? (hereinafter referred as Comments Comments “Offer Document”), Bank Statements, Postal Ballot Notice Whether shareholder approval has been Statutory Auditor obtained in case of material deviations from certificate^, Management No No expenditures disclosed in the Offer undertaking, Comments Comments Document? Shareholder’s resolution Statutory Auditor Whether the means of finance for the disclosed No No No certificate^, Management objects of the issue has changed? Comments Comments undertaking Source of information/ Comments Comments certifications considered of the Particulars Reply of the Board by Monitoring Agency Monitoring of Directors for preparation of report Agency Is there any major deviation observed over the No No earlier monitoring agency reports? Comments Comments Whether all Government/statutory approvals No No related to the object(s) have been obtained? Comments Comments Whether all arrangements pertaining to No No technical assistance/collaboration are in NA Statutory Auditor Comments Comments operation? certificate^, Management undertaking Are there any favorable events improving the No No viability of these object(s)? Comments Comments Are there any unfavorable events affecting the No No viability of the object(s)? Comments Comments Is there any other relevant information that No No may materially affect the decision making of No Comments Comments the investors? NA represents Not Applicable ^ Based on Certificate dated August 05, 2026, issued by M/s R V D & Co, Chartered Accountants (Firm Registration Number: 143936W), Statutory Auditor of the Company. 4) Details of object(s) to be monitored: i. Cost of the object(s): Source of Original Comments of the Board of information/ cost Directors Revised Comment of Sr. certification (as per the P [Showing first 8,000 characters — download PDF for full document]